WT 35023
Alternative Names: WT35023Latest Information Update: 28 Feb 2023
At a glance
- Originator Wellstat Therapeutics Corporation
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Macrophage inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Inflammation in USA
- 02 Feb 2021 Preclinical development is ongoing Inflammation in USA (Wellstat Therapeutics pipeline, January 2021)